Literature DB >> 22772914

Role of β2-adrenoceptor-β-arrestin2-nuclear factor-κB signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis.

Heng Fan1, Yi Liao, Qing Tang, Xiao-Yan Chen, Li-Juan Zhang, Xing-Xing Liu, Min Zhong.   

Abstract

OBJECTIVE: To investigate the β2-adrenoceptor (β2AR)-β-arrestin2-nuclear factor-κB (NF-κB) signal transduction pathway and the intervention effects of oxymatrine in a rat model of ulcerative colitis.
METHODS: Forty SD rats were randomly divided into four groups, which included the normal control group, the model group, the mesalazine group and the oxymatrine treatment group, with 10 rats per group. Experimental colitis induced with trinitrobenzene sulfonic acid (TNBS) was established in each group except the normal control group. The rats in the oxymatrine treatment group were treated with intramuscular injection of oxymatrine 63 mg/(kg·d) for 15 days and the rats in the mesalazine group were treated with mesalazine solution 0.5 g/(kg·d) by gastric lavage for 15 days. The rats in the normal control group and model group were treated with 3 mL water by gastric lavage for 15 days. Diarrhea and bloody stool were carefully observed. Histological changes in colonic tissue were examined on day 7 in 2 rats per group that were randomly selected. The expression of β2AR, β-arrestin2 and NF-κB p65 in colon tissue and spleen lymphocytes were detected with immunohistochemistry and Western immunoblotting techniques on day 16 after fasting for 24 h. Six rats died of lavage with 2 each in the normal control, the model group and the mesalazine group; and were not included in the analysis.
RESULTS: The rats in the model group suffered from looser stool and bloody purulent stool after modeling. But in the oxymatrine and mesalazine groups, looser stool and bloody purulent stool reduced after treatment. And the colonic wall in the model group was thickened and the colon length shortened. The colon mucosa was congested in multiple areas with edema, erosion, superficial or linear ulcer and scar formation, while the intestinal mucosa injury reduced in the mesalazine and oxymatrine groups (P<0.01). In colonic mucosa and in spleen lymphocytes, compared with the normal control group, the expression of NF-κBp65 were significantly increased (P<0.01) in the model group while the expressions of β 2AR and β-arrestin2 were significantly decreased (P<0.01). Compared with the model group, the expression of NF-κ Bp65 was significantly decreased in the mesalazine group (P<0.01) and oxymatrine treatment group (P<0.01) while the expressions of β2AR and β-arrestin2 were significantly increased (P<0.01). There were no statistically significant differences in the expression of β2AR, β-arrestin2 and NF-κBp65 between the mesalazine group and oxymatrine group (P>0.05).
CONCLUSIONS: The β2AR-β-arrestin2-NF-κB signal transduction pathway participated in the pathologic course of ulcerative colitis. Oxymatrine attenuated ulcerative colitis through regulating the β2AR-β-arrestin2-NF-κB signal transduction pathway.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772914     DOI: 10.1007/s11655-012-1146-3

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  24 in total

1.  Arresting NF-kappaB by beta-arrestin2.

Authors:  F Chen
Journal:  Cell Death Differ       Date:  2004-11       Impact factor: 15.828

2.  Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling.

Authors:  Yaya Wang; Yawei Tang; Lin Teng; Yalan Wu; Xiaohui Zhao; Gang Pei
Journal:  Nat Immunol       Date:  2005-12-25       Impact factor: 25.606

Review 3.  NF-kappaB and the intestine: friend or foe?

Authors:  Thomas Karrasch; Christian Jobin
Journal:  Inflamm Bowel Dis       Date:  2008-01       Impact factor: 5.325

Review 4.  Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis.

Authors:  R Balfour Sartor
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-07

5.  Anti-inflammatory mechanism of oxymatrine in dextran sulfate sodium-induced colitis of rats.

Authors:  Ping Zheng; Feng-Li Niu; Wen-Zhong Liu; Yao Shi; Lun-Gen Lu
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

6.  Effects of four regulating-intestine prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis.

Authors:  Heng Fan; Ming-Yi Qiu; Jia-Jun Mei; Guan-Xin Shen; Song-Lin Liu; Rui Chen
Journal:  World J Gastroenterol       Date:  2005-08-21       Impact factor: 5.742

7.  Oxymatrine improves TNBS-induced colitis in rats by inhibiting the expression of NF-kappaB p65.

Authors:  Heng Fan; Rui Chen; Lin Shen; Jianfang Lv; Pengcheng Xiong; Zhexing Shou; Xiong Zhuang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-08-15

Review 8.  The immunological and genetic basis of inflammatory bowel disease.

Authors:  Gerd Bouma; Warren Strober
Journal:  Nat Rev Immunol       Date:  2003-07       Impact factor: 53.106

Review 9.  NF-kappaB in inflammatory bowel disease.

Authors:  I Atreya; R Atreya; M F Neurath
Journal:  J Intern Med       Date:  2008-06       Impact factor: 8.989

10.  Effect of Wumeiwan on cytokines TNF-alpha, IL-6, IL-8, IL-10 and expression of NF-kappaBp65 in rats with ulcerative colitis.

Authors:  Heng Fan; Lin Shen; Qing Tang; Pengcheng Xiong; Zhexing Shou; Yi Liao; Li Liang; Xiaoyan Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-10-11
View more
  9 in total

Review 1.  β-Arrestins 1 and 2 are critical regulators of inflammation.

Authors:  Hongkuan Fan
Journal:  Innate Immun       Date:  2013-09-12       Impact factor: 2.680

2.  Differential Analysis of Serum Principal Components Treated with Compound Sophora Decoction and Related Compounds Based on High-Resolution Mass Spectrometry (HRMS).

Authors:  Wanjin Sun; Junjie Zhang; Conghui Zhou; Bin Yan; Quan Cai; Hongxia He; Xueyun Duan; Heng Fan
Journal:  Evid Based Complement Alternat Med       Date:  2020-09-30       Impact factor: 2.629

3.  Oxymatrine Sensitizes the HaCaT Cells to the IFN-γ Pathway and Downregulates MDC, ICAM-1, and SOCS1 by Activating p38, JNK, and Akt.

Authors:  Chun-Jie Gao; Pei-Jun Ding; Li-Li Yang; Xu-Feng He; Meng-Jiao Chen; Dong-Ming Wang; Yan-Xin Tian; Hui-Min Zhang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

Review 4.  The emerging roles of β-arrestins in fibrotic diseases.

Authors:  Yuan-jing Gu; Wu-yi Sun; Sen Zhang; Jing-jing Wu; Wei Wei
Journal:  Acta Pharmacol Sin       Date:  2015-09-21       Impact factor: 6.150

5.  Role of DOR-β-arrestin1-Bcl2 signal transduction pathway and intervention effects of oxymatrine in ulcerative colitis.

Authors:  Pi-Qi Zhou; Heng Fan; Hui Hu; Qing Tang; Xing-Xing Liu; Li-Juan Zhang; Min Zhong; Zhe-Xing Shou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

Review 6.  Five-aminosalicylic Acid: an update for the reappraisal of an old drug.

Authors:  Cristiana Perrotta; Paolo Pellegrino; Eliana Moroni; Clara De Palma; Davide Cervia; Piergiorgio Danelli; Emilio Clementi
Journal:  Gastroenterol Res Pract       Date:  2015-01-21       Impact factor: 2.260

Review 7.  Recent Trends in Pharmacological Activity of Alkaloids in Animal Colitis: Potential Use for Inflammatory Bowel Disease.

Authors:  Ana Cristina Alves de Almeida; Felipe Meira de-Faria; Ricardo José Dunder; Luis Paulo Bognoni Manzo; Alba Regina Monteiro Souza-Brito; Anderson Luiz-Ferreira
Journal:  Evid Based Complement Alternat Med       Date:  2017-01-09       Impact factor: 2.629

Review 8.  Sympathetic Nerve Hyperactivity in the Spleen: Causal for Nonpathogenic-Driven Chronic Immune-Mediated Inflammatory Diseases (IMIDs)?

Authors:  Denise L Bellinger; Dianne Lorton
Journal:  Int J Mol Sci       Date:  2018-04-13       Impact factor: 5.923

Review 9.  Targeting NF-κB pathway for treating ulcerative colitis: comprehensive regulatory characteristics of Chinese medicines.

Authors:  Peng-De Lu; Yong-Hua Zhao
Journal:  Chin Med       Date:  2020-02-10       Impact factor: 5.455

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.